Lenalidomide vs Thalidomide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: Cereblon E3 ubiquitin-ligase · full Multiple Myeloma pipeline

Lenalidomide

Marketed by Bristol-Myers Squibb and partners

Approved in Multiple Myelomasmall molecule (IMiD / cereblon modulator)
Reliable signal

NCT00056160 · Phase 3 · completed

This randomized, quadruple-blind, placebo-controlled Phase 3 trial enrolled 353 patients with previously treated multiple myeloma and used a hard clinical primary endpoint, time to tumor progression. The primary comparison was met: median TTP was 60.1 weeks (95% CI 41.1–80.0) with lenalidomide plus dexamethasone versus 20.1 weeks (95% CI 16.1–21.1) with placebo plus dexamethasone, a large, clearly favorable separation. The trial's strong design and positive primary result make this high-quality evidence for lenalidomide.

Next expected readout: November 2026 · NCT06505369 (registry estimate)

Reported efficacy

Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (From randomization up to cut-off date of 03 August 2005; up to 24 months); Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (Later Cut-off Date of 02 Mar 2008) (From randomization up to cut-off date of 02 March 2008; up to 51 months): Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (From randomization up to cut-off date of 03 August 2005; up to 24 months): Lenalidomide Plus Dexamethasone 52.1 weeks vs Placebo Plus Dexamethasone 20.1 weeks (95% CI 16.6 to 20.7) (met)

Result source: NCT00424047

Thalidomide

Marketed by Bristol-Myers Squibb

Approved in Multiple Myelomasmall molecule (IMiD / cereblon modulator, first-generation)
Partial signal

NCT00083551 · Phase 3 · completed

The trial randomly assigned 323 participants to thalidomide and 345 to no thalidomide, but treatment was open-label rather than blinded. Its primary endpoint was the hard clinical outcome of six-year overall survival; although the reported percentages favored thalidomide, statistical significance cannot be determined from the posted registry data.

Next expected readout: August 2027 · NCT00572169 (registry estimate)

Reported efficacy

Overall Survival (6 Years): Overall Survival (6 Years): Thalidomide 65 percentage of participants | No Thalidomide 58 percentage of participants (unclear)

Result source: NCT00083551

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLenalidomideThalidomide
PFS, median35.3 vs 21.8+13.5 vs placebon 351NCT01850524
13 other results
46.7bn 444NCT02541383
5 other results
OS, median39.3 vs 31.5+7.8 vs placebon 177NCT00056160
8 other results
49.8bn 168NCT00507416
2 other results
ORR78.5% vs 65.5%vs Lenalidomide + Dexamethasonen 321NCT01239797
12 other results
  • 82.5% 20/56 mg/m^2 once weekly · n 228 · Phase 3 · primary NCT03859427
  • 86.3% 20/27 mg/m^2 twice weekly · n 226 · Phase 3 · primary NCT03859427
  • 82% vs 80% n 351 · Phase 3 · secondary NCT01850524
  • 92.9% vs 76.4% n 281 · Phase 3 · secondary NCT02076009
  • 92.9% vs 81.6% n 368 · Phase 3 · secondary NCT02252172
  • 87.1% vs 66.7% n 396 · Phase 3 · secondary NCT01080391
  • 75.1% vs 62.3% n 535 · Phase 3 · secondary NCT00689936
  • 73.4% vs 62.3% n 541 · Phase 3 · secondary NCT00689936
  • 80.7% vs 67.5% n 535 · Phase 3 · secondary NCT00689936
  • 78.6% vs 67.5% n 541 · Phase 3 · secondary NCT00689936
  • 91.7% vs 75% n 48 · Phase 3 · secondary NCT02252172
  • 62.5% n 24 · Phase 3 · secondary NCT00928486
73%bn 147NCT00507416
3 other results
VGPR or better75.8% vs 44.2%vs Lenalidomide, Low-dose Dexamethasonen 281NCT02076009
1 other result
  • 81.5% vs 56.9% n 368 · Phase 3 · secondary NCT02252172
37%bn 147NCT00507416
2 other results
MRD negativity53.3% vs 35.4%vs Bortezomib-lenalidomide-dexamethasone (VRd)n 197NCT03652064
5 other results
  • 60.9% vs 39.4% n 197 · Phase 3 · primary NCT03652064
  • 59% vs 50% wk 72 · n 335 · Phase 3 · secondary NCT01850524
  • 32.1% vs 11.1% n 368 · Phase 3 · secondary NCT02252172
  • 18.9% 20/56 mg/m^2 once weekly · wk 52 · n 228 · Phase 3 · secondary NCT03859427
  • 18.1% 20/27 mg/m^2 twice weekly · wk 52 · n 226 · Phase 3 · secondary NCT03859427
—Not posted · NCT00083876

PFS, median

Lenalidomide
35.3 vs 21.8+13.5 vs placebon 351NCT01850524
13 other results
Thalidomide
46.7bn 444NCT02541383
5 other results

OS, median

Lenalidomide
39.3 vs 31.5+7.8 vs placebon 177NCT00056160
8 other results
Thalidomide
49.8bn 168NCT00507416
2 other results

ORR

Lenalidomide
78.5% vs 65.5%vs Lenalidomide + Dexamethasonen 321NCT01239797
12 other results
  • 82.5% 20/56 mg/m^2 once weekly · n 228 · Phase 3 · primary NCT03859427
  • 86.3% 20/27 mg/m^2 twice weekly · n 226 · Phase 3 · primary NCT03859427
  • 82% vs 80% n 351 · Phase 3 · secondary NCT01850524
  • 92.9% vs 76.4% n 281 · Phase 3 · secondary NCT02076009
  • 92.9% vs 81.6% n 368 · Phase 3 · secondary NCT02252172
  • 87.1% vs 66.7% n 396 · Phase 3 · secondary NCT01080391
  • 75.1% vs 62.3% n 535 · Phase 3 · secondary NCT00689936
  • 73.4% vs 62.3% n 541 · Phase 3 · secondary NCT00689936
  • 80.7% vs 67.5% n 535 · Phase 3 · secondary NCT00689936
  • 78.6% vs 67.5% n 541 · Phase 3 · secondary NCT00689936
  • 91.7% vs 75% n 48 · Phase 3 · secondary NCT02252172
  • 62.5% n 24 · Phase 3 · secondary NCT00928486
Thalidomide
73%bn 147NCT00507416
3 other results

VGPR or better

Lenalidomide
75.8% vs 44.2%vs Lenalidomide, Low-dose Dexamethasonen 281NCT02076009
1 other result
  • 81.5% vs 56.9% n 368 · Phase 3 · secondary NCT02252172
Thalidomide
37%bn 147NCT00507416
2 other results

MRD negativity

Lenalidomide
53.3% vs 35.4%vs Bortezomib-lenalidomide-dexamethasone (VRd)n 197NCT03652064
5 other results
  • 60.9% vs 39.4% n 197 · Phase 3 · primary NCT03652064
  • 59% vs 50% wk 72 · n 335 · Phase 3 · secondary NCT01850524
  • 32.1% vs 11.1% n 368 · Phase 3 · secondary NCT02252172
  • 18.9% 20/56 mg/m^2 once weekly · wk 52 · n 228 · Phase 3 · secondary NCT03859427
  • 18.1% 20/27 mg/m^2 twice weekly · wk 52 · n 226 · Phase 3 · secondary NCT03859427
Thalidomide
—Not posted · NCT00083876
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
10 other shared endpoints and safety

Coverage. Lenalidomide: 14 of 14 rows · Thalidomide: 14 of 14 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLenalidomide
Rows use multiple source trials
Thalidomide
Rows use multiple source trials
Complete
responder rate · % of participants
26% (n=351) vs 14% (n=354) placeboa,b
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
53.1% (n=98) vs 51% (n=96) Thalidomide + Prednisolone @ 52wka,b
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
1 other source trial
7.1% (n=112) vs 4.4% (n=113) Thalidomide + Dexamethasone*
NCT00097981 · Phase 3 · registry result, not featured evidence · combination · converted to % from 8 Participants as posted
Duration of Response
time to event · months
No placebo or comparator arm
NA months20/56 mg/m^2 once weeklyc,a,b
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
NA months20/27 mg/m^2 twice weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
18.3 monthsc,a,b
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
show 2 more doses
19.8 months
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
22.4 months
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
ORR
event count · % of participants
60.5% (n=177) vs 19.3% (n=176) placebo*a,b
NCT00056160 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to % from 107 Participants as posted
37.1% (n=35) vs 0% (n=33) ZLD @ 52wk*a,b
NCT00432458 · Phase 3 · registry result, not featured evidence · combination · converted to % from 13 participants as posted
ORR
responder rate · % of participants
No placebo or comparator arm
82.5% (n=228)20/56 mg/m^2 once weeklyc,a,b
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
86.3% (n=226)20/27 mg/m^2 twice weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
73% (n=147)c,a,b
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
show 2 more doses
70% (n=145)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
80% (n=133)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
Overall Survival
time to event · months
No placebo or comparator arm
NA months20/56 mg/m^2 once weeklyc,a,b
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
NA months20/27 mg/m^2 twice weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
49.8 monthsc,a,b
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
show 2 more doses
53.1 months
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
51.5 months
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
PFS
time to event · months
No placebo or comparator arm
7.45 months*c,a,d,b
NCT00405756 · Phase 3 · registry result, not featured evidence · combination · converted to months from 32.3 weeks as posted
show 1 more dose
25.85 months*
NCT00405756 · Phase 3 · registry result, not featured evidence · combination · converted to months from 112 weeks as posted
52.8 monthsc,a,d,b
NCT02541383 · Phase 3 · registry result, not featured evidence
show 1 more dose
46.7 months
NCT02541383 · Phase 3 · registry result, not featured evidence
Stringent Complete
responder rate · % of participants
35.6% (n=368) vs 15.7% (n=369) Lenalidomide + Dexamethasonea,b
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
28.6% (n=98) vs 26% (n=96) Thalidomide + Prednisolone @ 52wka,b
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
Time to Progression
time to event · months
13.87 vs 4.64 placebo months*a,b
NCT00056160 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to months from 60.1 weeks as posted
7 other source trials
12.02 vs 4.64 placebo months*
NCT00424047 · Phase 3 · combination · converted to months from 52.1 weeks as posted
12.09 vs 4.64 placebo months*
NCT00424047 · Phase 3 · combination · converted to months from 52.4 weeks as posted
NA vs 18.43 Lenalidomide, Low-dose Dexamethasone months
NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
NA vs 40.87 Lenalidomide + Dexamethasone months
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
45.8 vs 26.8 placebo months
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
14.47 vs 14.15 MPp+p months*
NCT00405756 · Phase 3 · registry result, not featured evidence · combination · converted to months from 62.7 weeks as posted
34.18 vs 14.15 MPp+p months*
NCT00405756 · Phase 3 · registry result, not featured evidence · combination · converted to months from 148.1 weeks as posted
28.8 vs 14.4 ZLD months*a,b
NCT00432458 · Phase 3 · registry result, not featured evidence · combination · converted to months from 2.4 years as posted
1 other source trial
13.4 vs 19.19 Thalidomide + Dexamethasone months*
NCT00097981 · Phase 3 · registry result, not featured evidence · combination · converted to months from 408 days as posted
Time to Response
time to event · months
No placebo or comparator arm
1 months20/56 mg/m^2 once weeklyc,e,a,b
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
1 months20/27 mg/m^2 twice weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
2 monthse,a,b
NCT00287872 · Phase 2 · registry result, not featured evidence · combination
Time to Treatment Failure
time to event · months
17.2 vs 14.1 Melphalan + Prednisone + Thalidomide monthsc,a,b
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
show 3 more doses
17.2 vs 14.1 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
16.9 vs 14.1 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
16.9 vs 14.1 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
16.5 vs 11.1 ZLD monthsa,b
NCT00432458 · Phase 3 · registry result, not featured evidence · combination
Dropout rate
63.8%f
NCT00056160 · Phase 3 · combination · Multiple Myeloma · phase 3
show 33 more results
—
NCT00424047 · Phase 3 · combination
n/a: no completion milestone
NCT03652064 · Phase 3 · registry result, not featured evidence
—
NCT03941860 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
n/a: no completion milestone
NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
n/a: no completion milestone
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
16.2%20/56 mg/m^2 once weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
—20/27 mg/m^2 twice weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
49.3%Ixazomib + LenDex
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—Ixazomib + LenDex (Exposure ≥19 Cy
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—Ixazomib+ LenDex (Exposure Up to 1
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
0.8%
NCT01335399 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
0.6%
NCT01239797 · Phase 3 · registry result, not featured evidence · combination
0%
NCT02322320 · Phase 3 · registry result, not featured evidence
0%
NCT01109004 · Phase 3 · registry result, not featured evidence
1%
NCT01080391 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—Lenalidomide and Dexamethasone (Rd
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneLenalidomide and Dexamethasone Rd1
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneLenalidomide and Low-Dose Dexameth
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneMPR+R
NCT00405756 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneMPR+p
NCT00405756 · Phase 3 · registry result, not featured evidence · combination
0%
NCT01621672 · Phase 3 · registry result, not featured evidence
—Lenalidomide ( ExtensionPhase) 22
NCT00622336 · Phase 3 · registry result, not featured evidence
—Lenalidomide (Treatment Phase) Up
NCT00622336 · Phase 3 · registry result, not featured evidence
—Lenalidomide and Dexamethasone
NCT00064038 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneLenalidomide+Dexamethasone
NCT00064038 · Phase 3 · registry result, not featured evidence · combination
40%
NCT00928486 · Phase 3 · registry result, not featured evidence · combination
56.4%
NCT00420849 · Phase 3 · registry result, not featured evidence · combination
51.3%
NCT00478777 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT00179647 · Phase 3 · registry result, not featured evidence
0%
NCT02969837 · Phase 2 · registry result, not featured evidence
—
NCT02619682 · Phase 2 · registry result, not featured evidence
6.1%
NCT03477539 · Phase 2 · registry result, not featured evidence
5%
NCT05032820 · Phase 2 · registry result, not featured evidence · combination
0%g
NCT00083551 · Phase 3 · combination
show 20 more results
—DVTd - Part 1
NCT02541383 · Phase 3 · registry result, not featured evidence · combination
—DVTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
—VTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
20.7%Bortezomib + Cyclophosphamide + De
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
—Bortezomib + Thalidomide + Prednis
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
0.6%
NCT00049673 · Phase 3 · registry result, not featured evidence
70.2%Bortezomib and Dexamethasone
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
68.3%Bortezomib, Melphalan and Predniso
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
74.9%Bortezomib, Thalidomide, and Dexam
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
14.3%
NCT00432458 · Phase 3 · registry result, not featured evidence · combination
89.3%
NCT00097981 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT01632150 · Phase 2 · registry result, not featured evidence · combination
—
NCT00040937 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00081939 · Phase 2 · registry result, not featured evidence
0%
NCT00083382 · Phase 2 · registry result, not featured evidence · combination
11.1%
NCT00458705 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00287872 · Phase 2 · registry result, not featured evidence · combination
0%1000 mg
NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination
0%800 mg
NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination
0%600 mg
NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination
Discontinued due to AEs
19.8%f
NCT00056160 · Phase 3 · combination · Multiple Myeloma · phase 3
show 33 more results
—
NCT00424047 · Phase 3 · combination
—
NCT03652064 · Phase 3 · registry result, not featured evidence
—
NCT03941860 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—
NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
—20/56 mg/m^2 once weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
—20/27 mg/m^2 twice weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
—Ixazomib + LenDex
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—Ixazomib + LenDex (Exposure ≥19 Cy
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—Ixazomib+ LenDex (Exposure Up to 1
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
0%
NCT01335399 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
0%
NCT01239797 · Phase 3 · registry result, not featured evidence · combination
—
NCT02322320 · Phase 3 · registry result, not featured evidence
—
NCT01109004 · Phase 3 · registry result, not featured evidence
—
NCT01080391 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
—Lenalidomide and Dexamethasone (Rd
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
13.1%Lenalidomide and Dexamethasone Rd1
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
12.7%Lenalidomide and Low-Dose Dexameth
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
20.4%MPR+R
NCT00405756 · Phase 3 · registry result, not featured evidence · combination
17.6%MPR+p
NCT00405756 · Phase 3 · registry result, not featured evidence · combination
—
NCT01621672 · Phase 3 · registry result, not featured evidence
—Lenalidomide ( ExtensionPhase) 22
NCT00622336 · Phase 3 · registry result, not featured evidence
—Lenalidomide (Treatment Phase) Up
NCT00622336 · Phase 3 · registry result, not featured evidence
—Lenalidomide and Dexamethasone
NCT00064038 · Phase 3 · registry result, not featured evidence · combination
—Lenalidomide+Dexamethasone
NCT00064038 · Phase 3 · registry result, not featured evidence · combination
8%
NCT00928486 · Phase 3 · registry result, not featured evidence · combination
18.2%
NCT00420849 · Phase 3 · registry result, not featured evidence · combination
19.3%
NCT00478777 · Phase 3 · registry result, not featured evidence · combination
15.4%
NCT00179647 · Phase 3 · registry result, not featured evidence
—
NCT02969837 · Phase 2 · registry result, not featured evidence
—
NCT02619682 · Phase 2 · registry result, not featured evidence
—
NCT03477539 · Phase 2 · registry result, not featured evidence
—
NCT05032820 · Phase 2 · registry result, not featured evidence · combination
—g
NCT00083551 · Phase 3 · combination
show 20 more results
—DVTd - Part 1
NCT02541383 · Phase 3 · registry result, not featured evidence · combination
—DVTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
—VTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
5.5%Bortezomib + Cyclophosphamide + De
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
—Bortezomib + Thalidomide + Prednis
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
—
NCT00049673 · Phase 3 · registry result, not featured evidence
34.5%Bortezomib and Dexamethasone
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
38.9%Bortezomib, Melphalan and Predniso
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
40.1%Bortezomib, Thalidomide, and Dexam
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
—
NCT00432458 · Phase 3 · registry result, not featured evidence · combination
39.3%
NCT00097981 · Phase 3 · registry result, not featured evidence · combination
17.5%
NCT01632150 · Phase 2 · registry result, not featured evidence · combination
—
NCT00040937 · Phase 2 · registry result, not featured evidence · combination
—
NCT00081939 · Phase 2 · registry result, not featured evidence
—
NCT00083382 · Phase 2 · registry result, not featured evidence · combination
8.9%
NCT00458705 · Phase 2 · registry result, not featured evidence · combination
—
NCT00287872 · Phase 2 · registry result, not featured evidence · combination
—1000 mg
NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination
—800 mg
NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination
—600 mg
NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination
Serious AEs
62.7%f
NCT00056160 · Phase 3 · combination · Multiple Myeloma · phase 3
show 33 more results
59.7%
NCT00424047 · Phase 3 · combination
72.1%
NCT03652064 · Phase 3 · registry result, not featured evidence
—
NCT03941860 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
72.4%
NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
79.4%
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
37.7%20/56 mg/m^2 once weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
32.5%20/27 mg/m^2 twice weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
—Ixazomib + LenDex
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
65.4%Ixazomib + LenDex (Exposure ≥19 Cy
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
73%Ixazomib+ LenDex (Exposure Up to 1
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
79%
NCT01335399 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
74.8%
NCT01239797 · Phase 3 · registry result, not featured evidence · combination
6.7%
NCT02322320 · Phase 3 · registry result, not featured evidence
20.6%
NCT01109004 · Phase 3 · registry result, not featured evidence
65.3%
NCT01080391 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
57%Lenalidomide and Dexamethasone (Rd
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
—Lenalidomide and Dexamethasone Rd1
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
71.1%Lenalidomide and Low-Dose Dexameth
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
44%MPR+R
NCT00405756 · Phase 3 · registry result, not featured evidence · combination
40.8%MPR+p
NCT00405756 · Phase 3 · registry result, not featured evidence · combination
72%
NCT01621672 · Phase 3 · registry result, not featured evidence
23.8%Lenalidomide ( ExtensionPhase) 22
NCT00622336 · Phase 3 · registry result, not featured evidence
53.6%Lenalidomide (Treatment Phase) Up
NCT00622336 · Phase 3 · registry result, not featured evidence
42.7%Lenalidomide and Dexamethasone
NCT00064038 · Phase 3 · registry result, not featured evidence · combination
—Lenalidomide+Dexamethasone
NCT00064038 · Phase 3 · registry result, not featured evidence · combination
48%
NCT00928486 · Phase 3 · registry result, not featured evidence · combination
57.9%
NCT00420849 · Phase 3 · registry result, not featured evidence · combination
54.9%
NCT00478777 · Phase 3 · registry result, not featured evidence · combination
45.9%
NCT00179647 · Phase 3 · registry result, not featured evidence
39.1%
NCT02969837 · Phase 2 · registry result, not featured evidence
13.3%
NCT02619682 · Phase 2 · registry result, not featured evidence
26.5%
NCT03477539 · Phase 2 · registry result, not featured evidence
22.5%
NCT05032820 · Phase 2 · registry result, not featured evidence · combination
100%g
NCT00083551 · Phase 3 · combination
show 20 more results
49.3%DVTd - Part 1
NCT02541383 · Phase 3 · registry result, not featured evidence · combination
18.8%DVTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
27.5%VTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
34.6%Bortezomib + Cyclophosphamide + De
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
27.2%Bortezomib + Thalidomide + Prednis
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
3%
NCT00049673 · Phase 3 · registry result, not featured evidence
53.3%Bortezomib and Dexamethasone
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
50.9%Bortezomib, Melphalan and Predniso
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
58.2%Bortezomib, Thalidomide, and Dexam
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
8.6%
NCT00432458 · Phase 3 · registry result, not featured evidence · combination
50%
NCT00097981 · Phase 3 · registry result, not featured evidence · combination
—
NCT01632150 · Phase 2 · registry result, not featured evidence · combination
1.3%
NCT00040937 · Phase 2 · registry result, not featured evidence · combination
100%
NCT00081939 · Phase 2 · registry result, not featured evidence
19.3%
NCT00083382 · Phase 2 · registry result, not featured evidence · combination
48.9%
NCT00458705 · Phase 2 · registry result, not featured evidence · combination
33.3%
NCT00287872 · Phase 2 · registry result, not featured evidence · combination
0%1000 mg
NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination
0%800 mg
NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination
33.3%600 mg
NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination
Most frequent reported AEs
f
fatigue 64.4% (placebo 60%)
neutropenia 49.2% (placebo 6.9%)
diarrhoea 48% (placebo 30.3%)
NCT00056160 · Phase 3 · combination · Multiple Myeloma · phase 3
show 27 more results
constipation 40.3% (placebo 23.4%)
neutropenia 40.3% (placebo 9.7%)
diarrhoea nos 38.1% (placebo 25.7%)
NCT00424047 · Phase 3 · combination
diarrhoea 56.3%
peripheral sensory neuropathy 55.8%
neutropenia 54.8%
NCT03652064 · Phase 3 · registry result, not featured evidence
neutropenia 65.4%
diarrhoea 59.7%
upper respiratory tract infection 43.5%
NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
diarrhoea 65.1%
neutropenia 61.5%
fatigue 44.8%
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
20/56 mg/m^2 once weekly
neutropenia 29.1%
anaemia 25.1%
hypertension 21.5%
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
20/27 mg/m^2 twice weekly
neutropenia 31.6%
hypertension 24.2%
anaemia 23.8%
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 77% (placebo 30%)
oedema peripheral 55.5% (placebo 32.5%)
constipation 48.2% (placebo 38.1%)
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
diarrhoea 41.7% (placebo 30%)
oedema peripheral 40.5% (placebo 32.5%)
constipation 36.2% (placebo 38.1%)
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
diarrhoea 51.8%
fatigue 49.3%
oedema peripheral 43.9%
NCT01335399 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
diarrhoea 50%
fatigue 48.4%
anaemia 42.5%
NCT01239797 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 43.4%
anaemia 42.3%
neutropenia 40.1%
NCT01080391 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
constipation 38.9%
diarrhoea 38%
anaemia 35.4%
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 46.6%
anaemia 44.5%
constipation 43.8%
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
neutropenia 78%
thrombocytopenia 68.7%
anaemia 66%
NCT00405756 · Phase 3 · registry result, not featured evidence · combination
neutropenia 76.3%
thrombocytopenia 65.8%
anaemia 59.9%
NCT00405756 · Phase 3 · registry result, not featured evidence · combination
grade 1 hypoalbuminemia 68%
grade 1 thrombocytopenia 52%
grade 2 leukopenia 36%
NCT01621672 · Phase 3 · registry result, not featured evidence
asthenia 14.3%
headache 14.3%
anaemia nos 9.5%
NCT00622336 · Phase 3 · registry result, not featured evidence
anaemia nos 0%
asthenia 0%
headache 0%
NCT00622336 · Phase 3 · registry result, not featured evidence
fatigue (asthenia, lethargy, malaise) 77.1%
hemoglobin 64.6%
glucose, serum-high (hyperglycemia) 55.2%
NCT00064038 · Phase 3 · registry result, not featured evidence · combination
neutropenia 80%
lymphopenia 64%
leukopenia 60%
NCT00928486 · Phase 3 · registry result, not featured evidence · combination
fatigue 42.4%
neutropenia 41.4%
muscle spasms 34.4%
NCT00420849 · Phase 3 · registry result, not featured evidence · combination
muscle spasms 24.3%
fatigue 22.9%
leukopenia 19.4%
NCT00478777 · Phase 3 · registry result, not featured evidence · combination
fatigue 56%
neutropenia 32.3%
muscle cramp 25.6%
NCT00179647 · Phase 3 · registry result, not featured evidence
fatigue 63%
diarrhea 45.7%
edema limbs 37%
NCT02969837 · Phase 2 · registry result, not featured evidence
lymphocyte decreased 36.7%
lymphocyte decreased 33.3%
wbc decreased 33.3%
NCT02619682 · Phase 2 · registry result, not featured evidence
platelet count decreased 93.9%
anemia 91.8%
neutrophil count decreased 83.7%
NCT03477539 · Phase 2 · registry result, not featured evidence
lymphocyte count decreased 85%
neutrophil count decreased 77.5%
white blood cell decreased 72.5%
NCT05032820 · Phase 2 · registry result, not featured evidence · combination
g
grade 1 bicarbonate decrease 60.1% (placebo 62.9%)
grade 1 hypokalemia 54.2% (placebo 52.8%)
grade 3 anemia (hgb) 49.8% (placebo 50.4%)
NCT00083551 · Phase 3 · combination
show 19 more results
peripheral sensory neuropathy 60.6%
constipation 50.6%
asthenia 32.8%
NCT02541383 · Phase 3 · registry result, not featured evidence · combination
bronchitis 40.6%
cough 17%
nasopharyngitis 17%
NCT02541383 · Phase 3 · registry result, not featured evidence
bronchitis 36.5%
cough 19.4%
nasopharyngitis 17.5%
NCT02541383 · Phase 3 · registry result, not featured evidence
constipation 35.8%
nausea 32.3%
peripheral sensory neuropathy 24.4%
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 37.9%
peripheral sensory neuropathy 36.9%
neuropathy peripheral 29.1%
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
neuropathy-sensory 89.1% (placebo 43.6%)
fatigue 72.7% (placebo 58.3%)
bone pain 72.1% (placebo 74.2%)
NCT00049673 · Phase 3 · registry result, not featured evidence
insomnia 5.5%
weight decreased 2.4%
blood sodium decreased 1.8%
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
leukopenia 7.4%
platelet count decreased 4.3%
insomnia 3.7%
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
hyperuricaemia 5.1%
insomnia 3.8%
cough 3.2%
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
peripheral sensory neuropathy 80%
fatigue 77.1%
constipation 62.9%
NCT00432458 · Phase 3 · registry result, not featured evidence · combination
oedema peripheral 56.6%
fatigue 54.7%
constipation 45.3%
NCT00097981 · Phase 3 · registry result, not featured evidence · combination
sensory neuropathy 78.9%
fatigue/malaise/lethargy 68.4%
hyperglycemia 51.3%
NCT00040937 · Phase 2 · registry result, not featured evidence · combination
grade 1 bicarbonate decrease 72.3%
grade 2 hypoalbuminemia 68.6%
grade 1 alkaline phosphatase increase 59.7%
NCT00081939 · Phase 2 · registry result, not featured evidence
grade 1 hypomagnesemia 56.6%
grade 2 fatigue 50.6%
grade 1 hypocalcemia 47%
NCT00083382 · Phase 2 · registry result, not featured evidence · combination
thrombosis/thrombus/embolism 17.8%
constipation 11.1%
diarrhea 8.9%
NCT00458705 · Phase 2 · registry result, not featured evidence · combination
peripheral neuropathy 83.3%
fatigue 73.3%
constipation 63.3%
NCT00287872 · Phase 2 · registry result, not featured evidence · combination
1000 mg
somnolence 100%
dysgeusia 66.7%
febrile neutropenia 66.7%
NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination
800 mg
diarrhea 100%
nausea 100%
somnolence 100%
NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination
600 mg
somnolence 100%
diarrhea 66.7%
mucositis 66.7%
NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bThe assessment timepoint is not available for both results.
  3. cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  4. dTreatment context has not been resolved for both arms.
  5. eTrial phases differ: Phase 3 versus Phase 2.
  6. fPopulation comparability has not been reviewed for 26 of these studies.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lenalidomide

Duration of Response 15.6 vs 7.68 placebo months
time to event · months
NCT00424047 · Phase 3 · combination · converted to months from 67.6 weeks as posted
show 11 more results
15.72 vs 7.68 placebo months*
NCT00424047 · Phase 3 · combination · converted to months from 68.1 weeks as posted
NA vs 17.4 Lenalidomide, Low-dose Dexamethasone months
NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
NA vs 43.7 Lenalidomide + Dexamethasone months
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
50.6 vs 37.5 placebo months
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
28.6 vs 21.2 Lenalidomide and Dexamethasone (Rd) months
NCT01080391 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
35 vs 22.3 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
22.1 vs 22.3 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
31.5 vs 22.1 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
21.5 vs 22.1 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
28.06 vs 12.78 MPp+p months*
NCT00405756 · Phase 3 · registry result, not featured evidence · combination · converted to months from 121.6 weeks as posted
12.95 vs 12.78 MPp+p months*
NCT00405756 · Phase 3 · registry result, not featured evidence · combination · converted to months from 56.1 weeks as posted
Time to ECOG Worsening 2.33 vs 2.84 placebo months
time to event · months
NCT00424047 · Phase 3 · combination · converted to months from 10.1 weeks as posted
show 1 more result
2.33 vs 2.84 placebo months*
NCT00424047 · Phase 3 · combination · converted to months from 10.1 weeks as posted
MRD Negative 53.3% (n=197) vs 35.4% (n=198) Bortezomib-lenalidomide-dexamethasone (VRd)
responder rate · % of participants
NCT03652064 · Phase 3 · registry result, not featured evidence
show 3 more results
60.9% (n=197) vs 39.4% (n=198) Bortezomib-lenalidomide-dexamethasone (VRd)
NCT03652064 · Phase 3 · registry result, not featured evidence
32.1% (n=368) vs 11.1% (n=369) Lenalidomide + Dexamethasone
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
59% (n=335) vs 50% (n=347) placebo @ 72wk
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
VGPR or Better 75.8% (n=281) vs 44.2% (n=276) Lenalidomide, Low-dose Dexamethasone
responder rate · % of participants
NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
show 1 more result
81.5% (n=368) vs 56.9% (n=369) Lenalidomide + Dexamethasone
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
ORR 92.9% (n=281) vs 76.4% (n=276) Lenalidomide, Low-dose Dexamethasone
responder rate · % of participants
NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
show 9 more results
92.9% (n=368) vs 81.6% (n=369) Lenalidomide + Dexamethasone
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
91.7% (n=48) vs 75% (n=44) Lenalidomide + Dexamethasone
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
82% (n=351) vs 80% (n=354) placebo
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
78.5% (n=321) vs 65.5% (n=325) Lenalidomide + Dexamethasone
NCT01239797 · Phase 3 · registry result, not featured evidence · combination
87.1% (n=396) vs 66.7% (n=396) Lenalidomide and Dexamethasone (Rd)
NCT01080391 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
75.1% (n=535) vs 62.3% (n=547) Melphalan + Prednisone + Thalidomide
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
73.4% (n=541) vs 62.3% (n=547) Melphalan + Prednisone + Thalidomide
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
80.7% (n=535) vs 67.5% (n=547) Melphalan + Prednisone + Thalidomide
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
78.6% (n=541) vs 67.5% (n=547) Melphalan + Prednisone + Thalidomide
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
Time to Response 1 vs 1.3 Lenalidomide, Low-dose Dexamethasone months
time to event · months
NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
show 7 more results
1.02 vs 1.87 placebo months
NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3
1.8 vs 2.8 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
1.8 vs 2.8 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
1.8 vs 2.8 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
1.8 vs 2.8 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
2.31 vs 3.74 MPp+p months*
NCT00405756 · Phase 3 · registry result, not featured evidence · combination · converted to months from 10 weeks as posted
2.15 vs 3.74 MPp+p months*
NCT00405756 · Phase 3 · registry result, not featured evidence · combination · converted to months from 9.3 weeks as posted
CR/sCR 51.1% (n=368) vs 30.1% (n=369) Lenalidomide + Dexamethasone
responder rate · % of participants
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
Time to First Response 1.05 vs 1.05 Lenalidomide + Dexamethasone months
time to event · months
Time to first response
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
Time to VGPR or Better 3.01 vs 4.7 Lenalidomide + Dexamethasone months
time to event · months
Time to VGPR or better
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
Time to Complete Response 10.66 vs 13.17 Lenalidomide + Dexamethasone months
time to event · months
Time to CR or better
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
Time to Best Response 9.97 vs 6.31 Lenalidomide + Dexamethasone months
time to event · months
Time to best response
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
Time to Next Treatment NA vs 42.4 Lenalidomide + Dexamethasone months
time to event · months
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
show 6 more results
39.1 vs 26.7 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
28.5 vs 26.7 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
36.7 vs 26.7 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
28.5 vs 26.7 Melphalan + Prednisone + Thalidomide months
NCT00689936 · Phase 3 · registry result, not featured evidence · combination
29.75 vs 15.3 MPp+p months*
NCT00405756 · Phase 3 · registry result, not featured evidence · combination · converted to months from 128.9 weeks as posted
15.25 vs 15.3 MPp+p months*
NCT00405756 · Phase 3 · registry result, not featured evidence · combination · converted to months from 66.1 weeks as posted

+ 116 further endpoints in the CSV export.

Thalidomide

CR or VGPR 92.9% (n=98) vs 81.3% (n=96) Thalidomide + Prednisolone @ 52wk
responder rate · % of participants
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
Disease-free Survival 13.37 vs 18.53 Thalidomide + Prednisolone months
time to event · months
NCT01539083 · Phase 3 · registry result, not featured evidence · combination
Overall Survival 30.1% (n=166) vs 36.7% (n=166) placebo @ 468wk
event count · % of participants
Death
NCT00049673 · Phase 3 · registry result, not featured evidence · converted to % from 50 Participants as posted
Progression Free Survival 60.2% (n=166) vs 76.5% (n=166) placebo @ 468wk
event count · % of participants
Disease progression
NCT00049673 · Phase 3 · registry result, not featured evidence · converted to % from 100 Participants as posted
Complete 3% (n=147)
responder rate · % of participants
No placebo or comparator arm
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
4% (n=133)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
4% (n=145)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
VGPR or Better 37% (n=147)
responder rate · % of participants
No placebo or comparator arm
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
51% (n=133)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
41% (n=145)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 GHS 1.3 score
absolute change · score
No placebo or comparator arm
Cycle 3, Day 1 (n=129, 115, 125)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
-4.4 score
Cycle 3, Day 1 (n=129, 115, 125)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
2 score
Cycle 3, Day 1 (n=129, 115, 125)
NCT00507416 · Phase 3 · registry result, not featured evidence · combination
PFS-12 85.7% (n=35) vs 54.5% (n=33) ZLD @ 52wk
event count · % of participants
NCT00432458 · Phase 3 · registry result, not featured evidence · combination · converted to % from 30 participants as posted
Overall 67.9% (n=112) vs 71.7% (n=113) Thalidomide + Dexamethasone
responder rate · % of participants
NCT00097981 · Phase 3 · registry result, not featured evidence · combination · converted to % from 76 Participants as posted
Time to First Response 1.91 vs 1.45 Thalidomide + Dexamethasone months
time to event · months
NCT00097981 · Phase 3 · registry result, not featured evidence · combination · converted to months from 58 days as posted
Overall Survival 19.6% (n=112) vs 18.6% (n=113) Thalidomide + Dexamethasone
event count · % of participants
NCT00097981 · Phase 3 · registry result, not featured evidence · combination · converted to % from 22 Participants as posted
PFS 77% (n=303) @ 156wk
responder rate · % of participants
No placebo or comparator arm
NCT00081939 · Phase 2 · registry result, not featured evidence

+ 3 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lenalidomide's landscape · Thalidomide's landscape